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Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with increased cardiovascular (CV)
mortality. Toll-like receptor-4 (TLR4) activates the innate immune response via NF-kB pathway and mitogen-
activated protein kinase signaling, leading to expression of proinflammatory cytokines and chemokines. The G
allele of TLR4 rs4986790 (+ 896A >G, Asp299Gly) gene polymorphism has been implicated in reduction of risk of
atherosclerosis. In this study, 1481 RA patients fulfilling the 1987 American College of Rheumatology (ACR)
criteria were genotyped for the rs4986790 TLR4 variant to determine the influence of this variant in the risk of CV
events in these patients. Also, HLA-DRB1 status was determined using molecular based methods. Moreover,
potential influence of rs4986790 variant in the development of subclinical atherosclerosis was assessed in a
subgroup of RA patients with no history of CV events by the measurement of surrogate markers of subclinical
atherosclerosis. No statistically significant differences in allele or genotype frequencies for the rs4986790 variant
between RA patients who experienced CV events or not were found. Likewise, no significant association be-
tween this gene variant and any of the surrogate markers of subclinical atherosclerosis was found. In summary,
results in our study do not support the hypothesis that the rs4986790 (+ 896A >G, Asp299Gly) TLR4 variant may
influence predisposition for subclinical atherosclerosis and clinically evident CV disease in RA patients.
Introduction
Rheumatoid arthritis (RA) is a complex autoimmunedisease associated with accelerated atherosclerosis
(Sattar et al., 2003; Gonza´lez-Gay et al., 2005). Besides tradi-
tional cardiovascular (CV) risk factors, chronic inflammation
(Gonza´lez-Gay et al., 2007) and genetic factors (Farragher
et al., 2008; Gonza´lez-Gay et al., 2009; Palomino-Morales et al.,
2009a, 2010a; Panoulas et al., 2009; Rodriguez-Rodriguez
et al., 2011c) have been implicated in the increased CV
mortality observed in RA patients.
Human toll-like receptors (TLRs) participate in the innate
response and signal the activation of adaptive immunity. The
toll-like receptor-4 (TLR4) plays an important role in the
recognition of microbial components, particularly lipopoly-
saccharides. In addition, TLR4 also interacts with endoge-
nous proteins present during inflammation such as oxidized
low-density lipoprotein, heat shock proteins 60 and 70, fi-
brinogen, and fibronectin (Akira et al., 2001; Xu et al., 2001).
TLR4 activates the innate immune response via the NF-kB
pathway and mitogen-activated protein kinase signaling,
through IRAK-1 and - 4 and TRAF6 (Huang and Pope, 2010)
leading to the expression of proinflammatory cytokines and
chemokines. TLR4 downregulates disease severity in exper-
imental autoimmune encephalomyelitis and Th17 cell re-
sponses, but promotes Th1 cell responses that may inhibit
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the differentiation of Th17 cells (Marta et al., 2009). A single-
nucleotide polymorphism (SNP) in the coding region of the
human TLR4 gene (rs4986790, + 896A >G) at exon 3 results
in amino acid exchange at position 299 (Asp299Gly). The
presence of Asp299Gly in Caucasian individuals alters the
structure of the extracellular domain of TLR4 (Akira et al.,
2001; Kiechl et al., 2002) because it is a change in the ligand-
binding site of the receptor (Rallabhandi et al., 2006).
TLR4 has been shown to be expressed by macrophages
and endothelial cells in human atherosclerotic lesions (Xu
et al., 2001; Edfeldt et al., 2002). Kiechl et al. reported that
carriers of the + 896G allele had lower levels of proin-
flammatory cytokines, acute-phase reactants, and soluble ad-
hesion molecules. They also found that these + 896G allele
carriers were more susceptible to severe bacterial infections
but had a lower risk of atherosclerosis manifested by a smaller
intima-media thickness in the common carotid (Kiechl et al.,
2002). Further, individuals with angiographically documented
coronary atherosclerosis treated with pravastatin that carried
the 299Gly were found to have lower risk of CV events during
follow-up than noncarriers (Boekholdt et al., 2003).
Some studies have reported association between TLR4
polymorphisms and susceptibility to RA (Radstake et al.,
2004). Although association of TLR4 polymorphisms
with other autoimmune diseases has also been described
(Marshak-Rothstein, 2006), in keeping with data from a re-
cent meta-analysis on association of TLR4 (+ 896A/G) gene
polymorphism with susceptibility to giant cell arteritis
(Alvarez-Rodriguez et al., 2011), a disease that like RA is
associated with HLA-DRB1*04 alleles (Gonza´lez-Gay et al.,
2003), Sa´nchez et al. (2004) did not confirm association of
TLR4 polymorphisms with RA in the Spanish population.
Also, no association of the TLR4 rs4986790 gene polymor-
phism with RA was found in Dutch (Emonts et al., 2011) and
French populations ( Jaen et al., 2009).
Despite those negative results, in the present study we
aimed to determine whether the common SNP of the TLR4
gene rs4986790 (+ 896A>G, Asp299Gly) may be associated
with the risk to develop CV disease in patients with RA,
given the crucial role of TLR4 in mediating inflammatory
signaling.
Materials and Methods
Patients
Between March 1996 and September 2008, 1481 consecu-
tive patients who fulfilled the 1987 American College of
Rheumatology classification criteria for RA (Arnett et al.,
1988) were recruited from the Rheumatology Outpatient
Clinics of Hospital Xeral-Calde (Lugo), Hospital Clı´nico San
Carlos (Madrid), Hospital Universitario La Paz (Madrid),
Hospital Universitario La Princesa (Madrid), Hospital Uni-
versitario Bellvitge (Barcelona), and Hospital Universitario
Marque´s de Valdecilla (Santander), Spain. Patients were as-
sessed for differences in the TLR4 rs4986790 gene variant.
Study protocol
Between December 2009 and January 2010, patient’s clin-
ical records were examined until patient’s death, loss of
follow-up, or December 1st, 2009. Information on the main
demographic data, clinical characteristics of the patients en-
rolled in the study, CV risk factors, and CV events of patients
are shown in Table 1. Two hundred and sixty-one (17.62%)
of these 1481 patients with RA experienced CV events.
Clinical definitions for CV events (ischemic heart disease,
heart failure, cerebrovascular accident, or peripheral arter-
iopathy) and classic CV risk factors were established as
previously described (Gonza´lez-Gay et al., 2007; Gonza´lez-
Juanatey et al., 2009).
To determine the potential association between the TLR4
rs4986790 polymorphism and the presence of subclinical
atherosclerosis, between March 2007 and September 2009 a
random subgroup of patients from the Lugo cohort with no
previous history of CV events was assessed. Presence of
endothelial dysfunction was established by a brachial artery
reactivity study in 134 patients. Flow-mediated endothelium-
dependent vasodilatation-FMD (post-ischemia) and endothelium-
independent-NTG (post-nitroglycerin) vasodilatation were
measured by brachial ultrasonography as previously re-
ported (Gonza´lez-Juanatey et al., 2003b; Gonza´lez-Gay et al.,
2008). Also, carotid ultrasonography studies were performed
in 112 patients to determine the carotid artery intima-media
wall thickness (IMT). It was assessed in the right common
carotid artery as earlier described (Gonza´lez-Juanatey et al.,
2006; Gonza´lez-Gay et al., 2008).
A subject’s written consent was obtained according to the
declaration of Helsinki, and the design of the work was ap-
proved by the Ethics Committee of Galicia (Spain). The
Ethics Committees of the Hospital Clı´nico San Carlos (Ma-
drid), Hospital La Paz (Madrid), Hospital de la Princesa
(Madrid), Hospital Universitario Bellvitge (Barcelona), and
Hospital Universitario Marque´s de Valdecilla (Santander)
also approved the study.
Genotyping
TLR4 genotyping. DNA was obtained from peripheral
blood using standard methods. Subjects were genotyped to
Table 1. Demographic Characteristics
and Genotype Distribution of Patients
with Rheumatoid Arthritis Included in the Study
Variables n = 1481
Females 1100 (74.27)
Age of patients at the time of
disease diagnosis, years, median (IQR)
54.2 (43–64)
Time follow-up, years, median (IQR) 10.6 (5.5–17)
anti-CCP positive (n = 1154) 672 (58.23)
Rheumatoid Factor positive (n= 1449) 1012 (69.84)
Shared epitope, presence (n = 753) 471 (62.55)
Rheumatoid arthritis subjects with
cardiovascular disease
261 (17.62)
Ischemic heart disease 141 (9.36)
Cerebrovascular accident 73 (4.85)
Heart failure 80 (5.32)
Peripheral arteriopathy 26 (1.73)
Hypertension (n = 1476) 579 (39.23)
Diabetes mellitus (n = 1470) 189 (12.86)
Dyslipidemia (n = 1445) 579 (40.07)
Obesity (n = 1401) 264 (18.84)
Smoking habit (n= 1427) 356 (24.95)
Except where indicated otherwise, values are n (%).
IQR, interquartile range; anti-CCP, anti-cyclic citrullinated peptide
antibodies.
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determine the TLR4 rs4986790 (+ 896A >G) polymorphism
located in exon 3, which leads to an aminoacid change As-
p299Gly (Arbour et al., 2000), using TaqMan Assays-on-De-
mand and analyzed using the ABI 7900HT Fast Real-Time
PCR System (Applied Biosystems, Foster City, CA), follow-
ing manufacturer’s instructions. Negative controls and du-
plicate samples were included to check the accuracy of
genotyping.
Shared epitope determination
Several HLA-DRB1 alleles (HLA-DRB1*0401, *0404, *0405,
*0408, *0101, *0102, *1001, *1402) are associated with sus-
ceptibility to RA. These alleles encode a conserved amino
acid sequence (QKRAA, QRRAA, or RRRAA), called the
shared epitope, at position 70–74 in the third hypervariable
region of the HLA-DRb1 molecule (Gregersen et al., 1987).
HLA-DRB1-shared epitope alleles are also implicated in the
severity of the disease (Gonza´lez-Gay et al., 2002). HLA-
DRB1 typing was carried out using a reverse dot-blot kit
with sequence-specific oligonucleotide (SSO) probes (Dynal
RELITM SSO HLA-DRB1 typing kit; Dynal Biotech, Brom-
borough, United Kingdom).
Statistical analysis
All genotype data were checked for deviation from
Hardy–Weinberg equilibrium (HWE) using http://ihg.gsf
.de/cgi-bin/hw/hwa1.pl. Comparison of proportions was
carried out using w2 test or Fisher test, when required.
Strength of associations between CV events and genotype or
alleles of TLR4 polymorphism were estimated using odds
ratios (OR) and 95% confidence intervals, via multiple lo-
gistic regression; estimates were further adjusted for gender,
age at RA diagnosis, time of follow-up, presence or absence
of the rheumatoid shared epitope, and classic CV risk factors
(hypertension, diabetes mellitus, dyslipidemia, obesity, and
smoking habit) as potential confounders.
The association between genotypes of the TLR4 poly-
morphism and surrogate markers of subclinical athero-
sclerosis: carotid IMT, FMD-endothelium dependent, or
NTG-endothelium independent vasodilatation were tested
using unpaired t-test, to compare between two groups, and
one-way analysis of variance to compare among more than
two groups. Moreover, we also tested association between
these parameters and alleles using analysis of covariance
(ANCOVA) adjusting for gender, age, and duration of the
disease at the time of the ultrasonographic study, and pres-
ence or absence of the rheumatoid shared epitope and classic
(traditional) CV risk factors. Statistical significance was de-
fined as p< 0.05. All analyses were performed with STATA
statistical software 9.1 (Stata Corp., College Station, TX).
Power for the study was calculated using ‘‘CaTS - Power
Calculator for Two Stage Association Studies’’ (www.sph
.umich.edu/csg/abecasis/CaTS/) (Skol et al., 2006).
Results
Frequencies of the TLR4 rs4986790 variant
and CV events in RA patients
The study had 74% statistical power to detect allelic ORs
greater than 1.65, based on calculation done from the asso-
ciation study in RA (Radstake et al., 2004) and reported in
biopsy-proven giant cell arteritis association study (Palomi-
no-Morales et al., 2009b), at the stated significance level
(a= 0.05), with a minor allele frequency of 0.06 and a prev-
alence of the disease in Spanish population 0.005 (Carmona
et al., 2002).
The study reached a genotyping success > 95%. Genotype
frequencies of the TLR4 rs4986790 variant studied were in
HWE equilibrium in the population under study. Minor al-
lele frequency of rs4986790 SNP was in keeping with other
studies previously reported (Radstake et al., 2004; Sa´nchez
et al., 2004; Palomino-Morales et al., 2009b), around 6% in
most European populations.
Table 2 shows the genotype frequencies of the TLR4
rs4689790 gene polymorphism assessed in this cohort of RA
patients stratified according to the presence or absence of CV
events. No statistically significant differences in the genotype
or allele frequency of the TLR4 rs4986790 ( + 896G >A) gene
polymorphism between RA patients who experienced CV
events or not were seen.
Also, no significant differences in the age at the onset of
the disease, rheumatoid factor, anti-cyclic citrullinated pep-
tide antibodies, shared epitope, and age at the time of disease
diagnosis were observed according to the different TLR4
rs4986790 genotypes in this series of RA patients (data not
shown).
To investigate a potential role of the TLR4 rs4986790 SNP
in the development of CV events, we assembled a logistic
regression model to explain the presence of CV disease in
patients with RA according to TLR4 rs4986790 allele distri-
bution adjusted for gender, age at the time of RA diagnosis,
follow-up time, presence or absence of shared epitope, and
classic CV risk factors, which did not disclose statistically
significant differences: p= 0.86, adjusted p= 0.68. Moreover,
no association with the TLR4 rs4986790 was found when we
Table 2. Differences in Genotype and Allele Frequencies of TLR4 rs4986790 Polymorphism Between
Rheumatoid Arthritis Patients with Cardiovascular Events or Without Cardiovascular Events
TLR4 rs4986790 With CV events Without CV events p-Value OR [95% CI]
AA 219 (87.95) 1039 (88.58) — Ref.
AG 29 (11.65) 127 (10.82) 0.71 1.08 (0.69–1.70)
GG 1 (0.40) 7 (0.60) 0.71 0.68 (0.03–5.50)
AG +GG 30 (12.05) 134 (11.42) 0.78 1.06 (0.68–1.65)
A 467 (93.78) 2205 (93.99) — Ref.
G 31 (6.22) 141 (6.01) 0.85 1.04 (0.68–1.58)
CV, cardiovascular; OR (95% CI), odds ratio with 95% confidence interval.
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specifically assessed the subtypes of CV events studied (is-
chemic heart disease, cerebrovascular accidents, peripheral
arteriopathy, or heart failure) (data not shown).
Since some studies suggested a potential role of TLR4 gene
in the risk of metabolic syndrome (Cuda et al., 2011) or type 1
diabetes mellitus (Kolek et al., 2004), we also sought for po-
tential association of the TLR4 rs4986790 polymorphism with
diabetes mellitus or dyslipidemia in our series. However, no
association was disclosed (data not shown).
TLR4 rs4986790 gene polymorphism
and subclinical atherosclerosis markers
Previous studies have shown an increased frequency of
subclinical atherosclerosis in RA patients without clinically
evident CV disease (Gonza´lez-Juanatey et al., 2003a, 2003b).
Because of that, we also aimed to establish the possible in-
fluence of this TLR4 polymorphism in the development of
subclinical atherosclerosis using two well-defined surrogate
markers of atherosclerosis, endothelial function, and the ca-
rotid IMT (Gonza´lez-Juanatey et al., 2006; Gonza´lez-Gay
et al., 2008), which have been proved to be predictors of
future CV events in asymptomatic stages of the atheroscle-
rotic disease (Gonza´lez-Gay et al., 2006; Full et al., 2009;
Emonts et al., 2011).
Although the results described in the present study con-
firmed the presence of endothelial dysfunction in patients
with long-standing RA (Gonza´lez-Gay et al., 2008), no asso-
ciation between TLR4 rs4986790 polymorphism and markers
of subclinical atherosclerosis was found in this series of RA
patients. Data from this series of patients with RA without
clinically evident CV disease stratified according to the ge-
notype distribution were the following:
Carotid IMT—mean (standard deviation [SD]): AA
(n = 104) 0.74mm (0.18), AG (n = 8) 0.65mm (0.12), GG (n = 0);
p = 0.20.
FMD%—mean (SD): AA (n = 124) 5.60 (4.93), AG (n = 10)
7.05 (4.72), GG (n = 0); p= 0.38.
No significant association in genotype distribution was
found for NTG% ( p= 0.34).
This study had> 90% statistical power to detect a differ-
ence in carotid IMT of 0.15mm or higher. Statistical power
was > 60% to detect a variation of 3.5% or higher in FMD-
endothelium-dependent vasodilatation.
In the ANCOVA model adjusted for gender, age at the
time of the ultrasonography assessment, follow-up time,
absence or presence of shared epitope, and traditional CV
risk factors, no significant differences were found according
to TLR4 rs4986790 alleles (TLR4 rs4986790 carotid IMT:
p = 0.93; FMD: p= 0.71; NTG: p = 0.94).
Discussion
Previous studies have described expression of TLR4 by
macrophages and endothelial cells within human athero-
sclerotic lesions (Xu et al., 2001; Edfeldt et al., 2002).
Association of TLR4 rs4986790 allele G polymorphism
with reduction of CRP levels and with decreased risk of
angiographic coronary artery disease and clinical diabetes
was observed in 1894 patients without acute myocardial
infarction (MI) undergoing coronary angiography (Kolek
et al., 2004). In keeping with this observation, a case-control
study on 183 patients with acute coronary syndromes and
216 controls disclosed that the TLR4 rs4986790 allele G was
associated with a decreased risk of coronary events inde-
pendent of the presence of classic CV risk factors (Ameziane
et al., 2003). Also, association of this variant with MI has been
described (Balistreri et al., 2004) in older subjects.
Taking into account these results that suggested a potential
influence of the TLR4 rs4986790 gene polymorphism in the
risk of atherosclerosis, we conducted a study in a large series
of patients with RA, a disease associated with accelerated
atherogenesis and increased incidence of CV events (Gonza´-
lez-Gay et al., 2005, 2006), to determine whether the TLR4
rs4986790 gene variant might also account for a decreased
incidence of CV events in white individuals with RA. How-
ever, our data did not confirm any association of the TLR4
rs4986790 gene polymorphism with the risk of CV events in
RA patients. It was also the case when we stratified RA pa-
tients according to the presence of specific CV events such as
coronary heart disease or cerebrovascular accidents. Inter-
estingly, our results in RA are in accordance with a study on
3657 patients with MI and 1211 controls with angio-
graphically normal coronary arteries and without signs or
symptoms of MI that did not show influence of the TLR4 gene
polymorphism in the risk of MI in Caucasian individuals
(Koch et al., 2006). Likewise, another study did not disclose
differences in the prevalence of the TLR4 rs4986790 genotypes
in patients with cerebral ischemia and control subjects (Re-
ismann et al., 2004). Moreover, when the TLR4 rs4986790 gene
polymorphism was assessed in 1400 patients from the
Southampton Atherosclerosis Study that were stratified ac-
cording to the presence of 0, 1, 2, or 3 coronary arteries with
> 50% stenosis, no significant differences in the genotype
distribution were observed (Yang et al., 2003). Further, to the
best of our knowledge, genome-wide association studies
(GWAS) have not shown associations between TLR4 gene and
RA disease susceptibility or CV traits (www.genome.gov/
gwastudies, accessed November 30th, 2011).
With regard to surrogate markers of atherosclerosis, a
study performed in 287 Dominicans from the Northern
Manhattan Study showed an association of carotid plaques
with genes involved in inflammation, including the TLR4
gene variant (Gardener et al., 2011). Also, the G allele of the
TLR4 gene—Asp299Gly- polymorphism was found to be
associated with increased carotid artery compliance in young
adults (Hernesniemi et al., 2008). Regrettably, in accordance
with these negative results in terms of CV events, no asso-
ciations of surrogate markers of subclinical atherosclerosis in
RA patients without clinically evident CV disease (carotid
IMT or endothelial function) with the TLR4 rs4986790 (A/G)
gene polymorphism were found in our study.
Our negative results are in line with previous reports of
our group on several gene polymorphisms implicated in the
inflammatory response that failed to establish an association
of gene polymorphisms with clinically evident CV disease or
subclinical atherosclerosis in Spanish RA patients: other gene
variants located outside the major histocompatibility com-
plex region (MHC) (PTPN22, STAT4, and TRAF1/C5), which
are also associated with increased disease susceptibility to
RA (Palomino-Morales et al., 2010b); polymorphisms impli-
cated in inflammation such as MIF-173 (Palomino-Morales
et al., 2010c) or vascular endothelial growth factor A (VEG-
FA) polymorphisms (Rodriguez-Rodriguez et al., 2011a), as
well. Neither association with CV disease was observed
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when distinct adipokines polymorphisms implicated in the
development of metabolic syndrome nor association with the
degree of inflammation in RA patients with severe disease
was assessed (Garcı´a-Bermu´dez et al., 2011; Rodriguez-Ro-
driguez et al., 2011b).
In conclusion, findings shown in our study do not support
the hypothesis that TLR4 rs4986790 ( + 896A >G, Asp299Gly)
polymorphism would be a risk factor for CV disease in pa-
tients with RA. However, since TLR4 is a mediator of in-
flammatory reactions (Akira et al., 2001) and atherosclerosis
is also an inflammatory disease, further studies in diverse
populations with different genetic backgrounds are needed
to completely exclude the role of the TLR4 rs4986790 gene
polymorphism in the development of the accelerated ath-
erosclerosis found in patients with RA.
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